FDA accepts Merck's grass pollen allergy treatment for review

03/29/2013 | Pharmaceutical Business Review Online · USA Today

Merck said the FDA has accepted its biologics-license application for an experimental immunotherapy to treat grass pollen allergy. Instead of providing temporary relief of allergy symptoms, the treatment targets the causes of the allergic reaction and reduces symptoms such as itching and sneezing gradually. Merck expects the agency to release its decision early next year.

View Full Article in:

Pharmaceutical Business Review Online · USA Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI